D-Serine Treatment For Tardive Dyskinesia

Status Active, not recruiting

Clinical Trial Summary

Presently no generally effective treatments for tardive dyskinesia (TD) are available. D-serine is a naturally occurring amino acid that acts in-vivo as positive allosteric modulator at the glycine site associated with the glutamatergic NMDA receptor. Previous studies have suggested that D-serine may improve motor symptoms, including dyskinesias, which are caused by treatment with presently used antipsychotics drugs.

The hypothesis under investigation in the present study is that D-serine adjuvant treatment may improve TD in schizophrenia patients diagnosed with this disorder.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Dyskinesias
Psychotic Disorders
Schizophrenia
Schizophrenia and Schizoaffective Disorder
Tardive Dyskinesia

Clinical Trial Details

NCT number	NCT01804920
Study type	Interventional
Source	Herzog Hospital
Contact
Status	Active, not recruiting
Phase	N/A
Start date	January 2013
Completion date	January 2019

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT02840760` - Repetitive Transcranial Magnetic Stimulation for the Treatment of the Tardive Dyskinesia.	N/A
Completed	`NCT01688037` - NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)	Phase 2
Completed	`NCT01391390` - Melatonin Treatment for Tardive Dyskinesia in Schizophrenia	N/A
Withdrawn	`NCT03254186` - Safety and Efficacy of Propranolol in the Treatment of Tardive Dyskinesia	Phase 2/Phase 3
Completed	`NCT02291861` - Addressing Involuntary Movements in Tardive Dyskinesia	Phase 3
Completed	`NCT02274558` - A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia	Phase 3
Completed	`NCT02198794` - Reducing Involuntary Movements in Participants With Tardive Dyskinesia	Phase 3
Completed	`NCT01467089` - The Assessment of Movement Disorders Utilizing Live Two-Way Video	N/A
Completed	`NCT04794413` - Pimavanserin Treatment in TS	Early Phase 1
Recruiting	`NCT06011408` - Remote Monitoring and Detecting of Tardive Dyskinesia for Improving Patient Outcomes	N/A
Recruiting	`NCT05859698` - Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia	Phase 4
Active, not recruiting	`NCT02252380` - ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders	N/A
Terminated	`NCT00917293` - Safety and Efficacy of Pyridoxal 5' -Phosphate in the Treatment of Tardive Dyskinesia	Phase 2
Completed	`NCT01543321` - Xenazine in Late Dyskinetic Syndrome With Neuroleptics	Phase 3
Completed	`NCT02405091` - Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia	Phase 3
Completed	`NCT03176771` - Efficacy and Safety of MT-5199 in Subjects With Tardive Dyskinesia	Phase 2/Phase 3
Terminated	`NCT02524886` - Deep Brain Stimulation for Patients With Tardive Dyskinesia and or Dystonia	N/A
Completed	`NCT02195700` - Aim to Reduce Movements in Tardive Dyskinesia	Phase 2/Phase 3
Completed	`NCT02736955` - Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia	Phase 3
Completed	`NCT03497013` - Effect of tDCS on Cognition, Symptoms in Chronic Schizophrenia Patients With Tardive Dyskinesia	N/A